The most influential cystic fibrosis advocacy groups in the United States and Europe have endorsed the idea of a Phase 1 clinical trial to test a triple-combo therapy that Proteostasis Therapeutics has developed, the company announced.
Proteostatis said the endorsements came from the Cystic Fibrosis Foundation’s and European CF Society’s clinical trial arms. The organization’s trial arm is called the Therapeutics Development Network and the European organization’s the Clinical Trial Network.
The main objectives of the trial are to test the combination’s ability to work in the body, its safety and CF patients’ ability to tolerate it. Researchers will also evaluate its ability to improve patients’ lung function.